Boehringer Ingelheim and Eli Lilly and Co. (LLY) said Tuesday that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for the development of Jardiance (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality following an acute myocardial infarction in patients with and without diabetes.
from RTT - Biotech https://ift.tt/33uuMrE
via IFTTT
No comments:
Post a Comment